Plasma Cell Myeloma Masquerading as Scleromyxedema

Area of Science:

• Dermatology
• Hematology
• Oncology

Background:

• Scleromyxedema is a rare, progressive cutaneous mucinosis of unknown cause, affecting men and women equally.
• It is frequently associated with monoclonal gammopathy, complicating treatment options.
• Established treatments like steroids, IVIg, stem cell transplant, and melphalan show limited efficacy.

Observation:

• A case of scleromyxedema was reported in a patient who was subsequently diagnosed with multiple myeloma.
• The patient presented with characteristic skin lesions of scleromyxedema.

Findings:

• The patient received six cycles of a specific chemotherapy regimen: bortezomib, thalidomide, and dexamethasone.
• This treatment resulted in complete resolution of all scleromyxedema skin lesions.

Implications:

• This case highlights a successful therapeutic approach for scleromyxedema, particularly when co-occurring with multiple myeloma.
• The bortezomib, thalidomide, and dexamethasone combination offers a promising treatment option for refractory scleromyxedema.
• Further research into this regimen's efficacy and safety in scleromyxedema patients is warranted.